The in vitro and in vivo results show that Lyp‐1 modification enhances the ability of targeted delivery to tumors and effectively inhibits the growth and metastasis of mouse breast cancer by combining PTT/PDT/chemotherapy. Here, PTPN22 is linked to breast cancer.